Since coronary artery and cerebrovascular diseases are the most common serious complications of long standing hypertension, there is a great potential for combining treatment with aspirin and angiotensin-converting enzyme inhibitors (ACE-I). However, the data regarding interaction of aspirin and ACE-I in relation to blood pressure control and survival benefits are controversial and inconclusive. We presumed that the appearance of dry cough in some of the patients following initiation of ACE-I treatment could be used as a marker for the presence of their influence, whereas ACE-I cough attenuation after addition of aspirin to treatment could be a sign of aspirin and ACE-I interaction on clinical level. The present study was aimed to use ACE-I induced cough as a clinical marker of ACE-I activity to determine whether dose-dependent aspirin and ACE-I interaction does exist. In a cohort of 750 consecutive ACE-I treated hypertensive and postinfarction outpatients we identified 78 (10.4%) non-smoking ACE-I related coughers. Out of them, 31 (21 men, 10 women; mean age 61 ± 0.9 years) agreed to take part in the study, which was aimed to compare two regimens of combined ACE-I and aspirin treatment (self-matched control data): intermediate (500 mg daily) vs low-dose aspirin (100 mg daily). On each visit the life quality, cough severity (CS, 0-4) and frequency (CF, 0-10) scores were registered. Low doses
Introduction
One of the most important cardiovascular effects of angiotensin-converting enzyme inhibitors (ACE-I) is to decrease arterial blood pressure, and this mediated not only by interference with renin-angiotensin II pathway, but also by an increase in bradykinin and in vasodilating prostaglandins 12 and E2. Cough severity and cough frequency scores decreased, respectively, from 2.7 ± 1.1 to 0.7 ± 1.2 (P Ͻ 0.001) and from 7.1 ± 2.3 to 2.0 ± 2.2 (P Ͻ 0.0001). Overall, the cough frequency score method alone could identify a clear modification of cough in 26 (84%) patients, and cough severity score method alone in 24 (77%). Using the combined frequency/severity score method a modification of cough could be identified in 28 (90%) of the patients receiving intermediate dose of aspirin. Aspirin did not influence heart rate and blood pressure control either in hypertensives or in postinfarction patients. We conclude that using ACE-I induced cough as a clinical marker of ACE-I activity demonstrates that an interaction between ACE-I and aspirin at 500 mg/day does exist. We did not find any evidence supporting the presence of a clinically significant interaction between ACE-I and aspirin at 100 mg/day. Thus, combined treatment by low dose aspirin and ACE-I seems to be both safe and useful. Since coronary artery and cerebrovascular diseases are the most common serious complications of long standing hypertension, there is a great potential for combined treatment with aspirin and ACE-I. However, the data regarding interaction of aspirin and ACE-I in relation to blood pressure control and survival benefits are controversial and inconclusive. Several studies discerned that aspirin antagonises ACE-I in antihypertensive [2] [3] [4] and heart failure 5, 6 management, whereas others found no such interactions. [7] [8] [9] [10] [11] This prominent disagreement among the studies might be explained partially by difficulties to find a clear clinical marker for aspirin/ACE-I interactions, especially in short-term clinical investigations.
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A dry bothersome cough is the most common adverse class effect of all ACE-I without clear differences between agents; recent studies indicate that cough occurs in about 10% of patients treated by ACE-I. [12] [13] [14] Bradykinin and prostaglandins (PG) have been suggested to play a leading role in the genesis of ACE-I associated cough [15] [16] [17] [18] [19] [20] and we have previously reported that aspirin might interfere with these process. 21 We presumed that the appearance of dry cough in part of the patients following initiation of ACE-I therapy could be used as a marker of their influence, whereas ACE-I cough attenuation after addition of aspirin to treatment is a sign of aspirin and ACE-I interaction on clinical level. The present selfmatched control study was aimed to use ACE-I induced cough as a clinical marker of ACE-I activity and to determine whether dose-dependent aspirin and ACE-I interaction exists.
Materials and methods

Patients
Over a 9-month period, out of 750 consecutive ACE-I treated hypertensive and postinfarction outpatients we identified 78 (10.4%) non-smoking ACE-I related coughers. Following a careful clinical evaluation, 19 patients with symptomatic heart failure, asthma or concomitant treatment by NSAID were excluded. The remaining 59 eligible patients were informed about the purpose of the study. Out of them, 31 patients (21 men, 10 women; mean age 61 ± 0.9 years) agreed to take part in the study.
The study was designed to compare two different regimens of combined ACE-I and aspirin treatment (self-matched control data): intermediate (500 mg daily) vs low-dose aspirin (100 mg daily). After an informed consent had been obtained, ACE-I treatment was discontinued and the dry cough completely disappeared, but returned in all patients within 1 week (rechallenge period) after ACE-I reintroducing.
At the end of rechallenge period (visit 1), patients started a low dose of aspirin (100 mg once daily) for 1 week (visit 2), switching thereafter to the intermediate dose of aspirin (500 mg once daily) for an additional week (visit 3).
Cough scores
On each of the visits at the outpatient clinic, patients were asked to mark in a self-administered questionnaire the score (0-4) for the severity of cough. For the purposes of this study, severity of cough was defined as follows: 0-no cough at all; 1-occasional hems; 2-mild, isolated cough, without additional symptoms; 3-moderate, paroxysmal cough, without additional symptoms; 4-severe, strenuous cough, accompanied by chest discomfort.
In addition to cough severity score, cough frequency score (0-10) was obtained using a scale accordingly to Malini et al:
22 0 = I never cough; 10 = I cough all day. While filling in the scores, patients had no access to previous results. Evaluation of symptoms was accompanied by blood pressure and heart rate measurements and by a clinical evaluation to exclude disorders predisposing to cough (eg, recent respiratory tract infections). Arterial blood pressure was measured in a sitting position with a standard clinical mercury sphygmomanometer and an appropriate cuff size, in accordance with the guidelines of the American Heart Association. 23 
Statistical analyses
All values were reported as mean ± standard deviation (s.d.) and range. Blood pressure and heart rate were analysed using paired t-test, scores were compared by nonparametric Wilcoxon signed rank test; significance was defined as P Ͻ 0.05.
Results
Of the 31 patients, eight were on ramipril, seven on enalapril, six on cilazapril, five on captopril, three on fosinopril, and two on benazepril. There were 19 patients taking ACE-I for hypertension, seven for left ventricular dysfunction after myocardial infarction and five for both reasons. In 17 patients concomitant treatment included beta-blockers, famotidine (n = 9), and calcium channel blockers (n = 11). All patients completed the study.
Low doses of aspirin demonstrated an excellent safety profile and did not influence any life quality score (Table 1) and ACE-I induced cough (Table 2) . In contrast, intermediate doses completely abolished cough in 17 patients, reduced coughing in other 11, and did not influence on the remaining three. Cough severity and cough frequency scores decreased, respectively, from 2.7 ± 1.1 to 0.7 ± 1.2 (P Ͻ 0.001) and from 7.1 ± 2.3 to 2.0 ± 2.2 (P Ͻ 0.0001). According to patients' impressions, cough subsided sharply within 24 h of starting the intermediate doses of aspirin; this effect was maintained throughout the whole study period.
Overall, the cough frequency score method alone could identify a clear modification of cough in 26 (84%) patients and cough severity score method alone in 24 (77%). Using combined frequency/ severity score method a modification of cough could be identified in 28 (90%) of patients receiving intermediate dose of aspirin.
The dizziness and tiredness scores were not ACE-I = angiotensin converting enzyme inhibitor; ASA = acetyl salycilic acid (aspirin); CFS = cough frequency score; CSS = cough severity score; DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure.
changed by aspirin, the headache score decreased and the abdominal discomfort score increased (but did not force discontinuation of treatment) by using the intermediate dose of aspirin (Table 1) . Aspirin did not influence heart rate and blood pressure control either in hypertensives or in postinfarction patients ( Table 2 ).
Discussion
The main finding of our study is that a low dose of aspirin (100 mg daily) did not demonstrate any influence on ACE-I induced cough. In contrast, aspirin in a dose of 500 mg daily could strongly attenuated ACE-I induced cough in the majority of the patients. Neither in hypertensives nor in postinfarction patients did aspirin influence blood pressure control regardless of its dose.
Theoretical basis for the ACE-I/aspirin interaction
The main mechanisms of ACE-I therapeutic effects are related both to angiotensin II production hindrance and bradykinin accumulation. In turn, this accumulation leads to prostacyclin release and Larginine-nitric oxide pathway enhancement, favouring also the cardiovascular action of ACE-I. The importance of L-arginine-nitric oxide pathway in vascular endothelial protection is recognised. 24, 25 However, it should be pointed out that bradykinin may be responsible for ACE-I induced side effects like cough-and these undesirable reactions may
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The connection of PG to cough response to ACE-I A is widely supported. [15] [16] [17] [18] [19] [20] [21] [22] 26 Aspirin acetylation leads to irreversible inhibition of cyclooxygenase (PGH synthase)-which is the first enzyme of PG synthesis-converting arachidonic acid to PGH2. 27, 28 This enzymatic step explains the ambivalent action of aspirin which inhibits the production of both prostacyclin (vasodilator and antithrombotic) and thromboxanes (prothrombotics, broncho-and vasoconstrictors. 29, 30 In general, prostaglandins play an important endogenous vasodilatory role and counteract the enhanced peripheral vasoconstriction state in hypertension and congestive heart failure. 31 It was suggested, that inhibition of PG synthesis by aspirin may result in vasoconstriction and might reduce the beneficial effects of ACE-I on blood pressure and heart failure management.
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Are interactions between ACE-I and aspirin dosedependent?
The data regarding interaction of aspirin and ACE-I in relation to survival benefits and blood pressure control are inconclusive. Several reports discerned that aspirin antagonises ACE-I in antihypertensive [2] [3] [4] and heart failure, 5, 6, 32 management, whereas others found no such interactions. 10, 11 Aspirin and ACE-I in these studies were used in different doses. In
Journal of Human Hypertension most of the studies used aspirin in low doses (Ͻ250 mg/day) the attenuation of the benefits of ACE-I were not found, 7,9 whereas higher aspirin dosages may produce a significant negative interaction. 31 Another source for the discrepancies between results may be related to the fact that systemic ACE concentrations do not necessarily reflect tissular concentrations. 33 A possible explanation for the current controversies may be based on that interactions between ACE-I and aspirin are dose-dependent: a combination of partial agonism and antagonism between aspirin and ACE-I at multiple levels may explain the complex dose-dependent interrelationship between these agents.
In addition, aspirin may have an adverse effect on outcome in patients with heart failure that is independent of any interaction with ACE-Is, possibly by blocking endogenous vasodilator prostaglandin production and enhancing the vasoconstrictor potential of endothelin.
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ACE-I induced cough as a clinical marker of ACE-I activity
To the best of our knowledge, the present study is the first clinical report employed ACE-I induced cough as a clinical marker of ACE-I activity. We demonstrated that certain interaction between ACE-I and aspirin in dose 500 mg/day really exists. We did not find any evidence supporting the presence of clinically significant interaction between ACE-I and aspirin in dose 100 mg/day. Thus, combined treatment by low dose aspirin and ACE-I seems to be both safe and useful.
In our study there were only three patients whose cough failed completely to respond to aspirin. Recent studies have shown that 10-15% of patients have a poor response to aspirin. It is unclear if these observations reflect absorption problems or altered pharmacodynamics. 27, 34 Aspirin in hypertensive patients: clinical implications and future research Coronary artery and cerebro-vascular diseases are the most common serious complications of long standing hypertension. The widespread use of aspirin probably contributes significantly to reduction of cardiovascular morbidity and mortality among high risk hypertensive patients with concomitant cardiovascular problems 35 and therefore there is a great potential for combined treatment with aspirin and ACE-I. Evidences emerging from randomised trials in patients with ischaemic heart disease show that aspirin in low, 36 intermediate 37 and high doses 38 bears a very similar extent of favourable effects on survival. Particularly, after myocardial infarction in the absence of heart failure, the overall benefits of both ACE-I and aspirin are well established and, although the benefit from the combination may be reduced, the combination will still be better than either used alone. 39, 40 Aspirin use among patients being evaluated for known or suspected coronary artery disease was independently associated with reduced long-term all-cause mortality in a recent observational study. 41 Based on our data, we support the combined use of ACE-I and aspirin, if clinically indicated, but implementation of low aspirin doses appears to be preferable as a first-line strategy.
Study limitations
The present study did not include a placebo group since it was designed to compare two different regimens of active treatment, so that each of them represented in fact a control for the other one (selfmatched control data). Obviously, more information could be received from a double-blind study, compared with an open-label albeit self-matched control trial. The patient population is relatively small. Therefore, some caution ought be used in drawing conclusions regarding our observations.
Further investigations are warranted to explore the basis for the different interactions between ACE-I and various aspirin doses.
Conclusions
Using ACE-I induced cough as a clinical marker of ACE-I activity we demonstrated that a certain interaction between ACE-I and aspirin at 500 mg/day exists. We did not find any evidence supporting the presence of clinically significant interaction between ACE-I and aspirin at 100 mg/day. Thus, combined treatment by low-dose aspirin and ACE-I seems to be both safe and useful.
